FIELD: biotechnology.
SUBSTANCE: continuous methods of preparing an antibody-drug conjugate (ADC) composition are provided. These methods use continuous conjugation processes, single pass tangential flow filtration, countercurrent diafiltration and/or inline process automation technologies.
EFFECT: methods reduce the time and cost of the processes and improve the stability of the product.
45 cl, 14 dwg, 8 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| CONJUGATES OF ANTIBODY TO CCR7 AND DRUG | 2018 |
|
RU2777662C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
